Top Markets
Coin of the day
Alimera Sciences, Inc. Alimera Sciences, Inc.

Alimera Sciences, Inc.

ALIM
Classement en actions #26668
Alimera Sciences, Inc. is a pharmaceutical company focused on developing and... Alimera Sciences, Inc. is a pharmaceutical company focused on developing and commercializing ophthalmic treatments globally, including in the United States. Its primary offering, ILUVIEN, is an intravitreal implant used to manage diabetic macular edema (DME), a severe retinal disease in individuals with diabetes that can lead to profound vision loss and blindness. Additionally, ILUVIEN helps prevent relapses of recurrent non-infectious uveitis affecting the posterior segment of the eye. The company distributes its products directly and through distributors to various healthcare entities such as physician offices, pharmacies, and hospitals. Alimera also maintains a collaboration with EyePoint Pharmaceuticals US, Inc. focused on developing and marketing insert technology. This technology is designed to deliver corticosteroids to the back of the eye for treating and preventing various human eye diseases, including diabetic macular edema. Founded in 2003, Alimera Sciences is headquartered in Alpharetta, Georgia.
Prix de l'action
$5.54
Dernière synchronisation: 2024-09-18
Capitalisation boursière
$38.76M
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange Alimera Sciences, Inc. (ALIM)

Catégorie

Bénéfices pour Alimera Sciences, Inc. (ALIM)
Bénéfices en Jun 2024 TTM : $-14.71M
Selon les derniers rapports financiers de Alimera Sciences, Inc., les bénéfices actuels de l'entreprise sont de $-14.71M. En 2022, l'entreprise a réalisé un bénéfice de $-18.08M, une diminution par rapport à celui de 2021 qui était de $-3.93M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Alimera Sciences, Inc. de 2006 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
2026 (TTM) $-14.71M -26.61%
2023 $-20.05M 10.89%
2022 $-18.08M 359.56%
2021 $-3.93M -27.24%
2020 $-5.41M -47.13%
2019 $-10.23M -37.17%
2018 $-16.28M -25.47%
2017 $-21.84M -33.83%
2016 $-33.00M 8.15%
2015 $-30.52M -14.61%
2014 $-35.74M -22.70%
2013 $-46.23M 134.12%
2012 $-19.75M -12.30%
2011 $-22.52M 32.74%
2010 $-16.96M -59.95%
2009 $-42.36M -30.03%
2008 $-60.54M 383.70%
2007 $-12.52M 20.64%
2006 $-10.37M 0.00%
Bénéfices des entreprises similaires ou concurrentes